A
Acclaro Medical
UltraClear is the world's first cold fiber fractionated laser solution
About Acclaro Medical
UltraClear Laser, developed by Acclaro Medical, is a pioneering company in the aesthetic laser industry, offering the world's first cold fiber fractionated laser solution for skin rejuvenation. This innovative technology minimizes unwanted thermal damage while maximizing results for all skin types, significantly reducing pain and recovery time. The company serves a diverse clientele, including individuals seeking treatments for fine lines, deep wrinkles, sun spots, age spots, scars (including acne scars), and large pores. Operating in the global aesthetic and dermatological market, UltraClear Laser's business model revolves around selling advanced laser equipment to dermatologists, cosmetic surgeons, and medical spas. Revenue is generated through the sale of laser devices, maintenance services, and consumables. The company's technology stands out due to its superior efficacy, safety, and ability to deliver outstanding results with minimal discomfort and short downtime.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2025 | $23M | $92M | Accelmed · 3E Bioventures | ↗ |
Growth signals
Latest recorded traffic for Acclaro Medical is 8.5K monthly website visits, down 82.3% over the last three months. Acclaro Medical's team grew 126.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Acclaro Medical in the Smithfield ecosystem
The Acclaro Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Accelmed
3E Bioventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acclaro Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acclaro Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







